'At Gilead Sciences, they’re popping champagne corks. They’ve got a blockbuster drug, a once in a lifetime winner, Sovaldi. As FiercePharma reports:
“With a revolutionary approach to hepatitis C and a price tag of $84,000 per 12-week treatment course, analysts expected big sales from Gilead’s Sovaldi. Some even forecast it would reach $9 billion or more by 2017, at which level it would surpass Pfizer’s Lipitor to take the crown for biggest-selling drug of all time. But none expected the exponential growth the drug is posting right now…”
A drug for hepatitis C. What a drug, what a price. $84,000 for 12 weeks of treatment.
So…what is hepatitis C?'
Read more...
